Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CareFusion

This article was originally published in The Gray Sheet

Executive Summary

Vertebroplasty device maker CareFusion plans to enter the estimated $500 million-$600 million kyphoplasty market with the April launch of a new device in its AVAmax line, the firm said during its Feb. 9 second-quarter 2010 earnings call. Medtronic's Kyphon kyphoplasty balloon spine stabilization system currently leads the market. CareFusion downplayed the threat of intellectual property battles, saying Medtronic's patents were either expired or unrelated to CareFusion's device, though J.P. Morgan analyst Michael Weinstein expects Medtronic to initiate legal action closer to U.S. launch. CareFusion, which spun off from Cardinal Health last September, recorded second-quarter revenues of $1.02 billion, up 5%, or 2% on a constant currency basis, from the prior-year quarter
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel